Our Principal, Yolanda Wang, just returned from the 1st China Pharmaceutical Innovation Conference (CPIC 2026) in Shanghai, held from July 22–24!

It was a pleasure to attend CPIC 2026 together with fellow HKBMIA members and connect with biotech innovators from around the world. Many thanks to HKBMIA for the invitation and the opportunity to engage with industry partners. Hong Kong continues to play an important role in connecting Mainland China with the global life sciences community.

Bringing together over 10,000 participants, CPIC highlighted the strong momentum behind cross-border biopharma innovation and collaboration. It was great to see so many discussions focused on advancing healthcare innovation and building new partnerships across borders. The strong presence of AI-related healthcare and drug development initiatives was particularly impressive and reflected the rapid evolution of China’s innovation ecosystem. As IP professionals, we are reminded of the important role that IP plays in supporting innovation and bringing new technologies to market.

我们的过去活动

Pauli Wong gave a talk at Hong Kong Life Sciences Society (HKLSS)

2026年10月10日

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Recommended Insights

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
阅读更多 >

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
阅读更多 >

From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

2025年10月21日
As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as 'the Guidelines') included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to […]
阅读更多 >

Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments

2026年7月22日
Managing global pharmaceutical or chemical portfolios requires navigating China’s notoriously rigid standards on the "same subject matter" requirement for priority and claim amendments. A recent invalidation decision (No. 588094) issued by the China National Intellectual Property Administration (CNIPA) concerning a pharmaceutical patent provides clarity on how numerical ranges and later added experimental data are evaluated […]
阅读更多 >
Top crossarrow-right